• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Mupirocin effective in Staphylococcus aureus decolonization in neonates

byKate AndersonandCordelia Ross
December 26, 2018
in Infectious Disease, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Mupirocin was shown to have an overall primary decolonization efficacy of 95% when used to treat Staphylococcus aureus among infants <24 months old admitted to the neonatal intensive care unit (NICU).

2. Almost half of all treated patients who demonstrated primary decolonization and remained in the hospital at day 22 also demonstrated persistent decolonization.

Evidence Rating Level: 1 (Excellent)

Study Rundown: S. aureus colonization is a major source of sepsis, morbidity, and mortality among infants admitted to the NICU. Previous studies have shown prophylactic mupirocin administration among adults admitted to the intensive care unit to be efficacious in preventing hospital acquired MRSA infections, however its effect on critically ill infants has not been studied. In this trial, researchers evaluated the safety and efficacy of mupirocin (intranasal, periumbilical, and perianal) versus no mupirocin in reducing primary and persistent colonization with S. aureus (both methicillin-sensitive, MSSA, and methicillin-resistant, MRSA) among NICU patients <24 months old. Results showed mupirocin use had an overall efficacy of about 95% in primary colonization with S. aureus in the study population. Almost half of the infants who demonstrated primary decolonization and who remained in the hospital at day 22 also demonstrated persistent decolonization. Rash was the only adverse reaction noted significantly more often in treated patients. This study was limited by potential reporting bias in that nurses were asked to examine all treated patients for rash prior to mupirocin application. Although this study was not powered to determine the efficacy of mupirocin use in preventing S. aureus infections, results suggest mupirocin use at several body sites could be used to decrease S. aureus colonization rates among infants in the NICU.

Click to read the study, published today in Pediatrics

Relevant reading: The epidemiology of methicillin-susceptible and methicillin-resistant Staphylococcus aureus in neonatal intensive care unit, 2000-2007

In-depth [randomized controlled trial]: This study analyzed the efficacy and safety of mupirocin versus no mupirocin in S. aureus decolonization. Participants included 155 infants <24 months old (56% male) who were accepted to remain in the NICU for >14 days and who tested positive for S. aureus via nasal swab shortly after admission. Patients were stratified into 4 groups, initially based on gestational and postnatal age (27% <28 weeks gestation), then by methicillin sensitivity (86% MSSA, 14% MRSA or MRSA+MSSA). Patients were randomly assigned in a 1:1 ratio to receive 5 days of mupirocin (applied to the intranasal, periumbilical, and perianal regions) vs. no mupirocin. Patients were monitored for adverse events and swabbed in all 3 regions at days 8 and 22 to evaluate for primary and persistent decolonization. Results showed primary decolonization occurred in 94% of treated patients vs. 5% of control patients (overall efficacy 95%). Of the infants remaining in the hospital at day 22, 46% of treated infants vs. 2% of the control group demonstrated persistent decolonization. Rash was the only adverse reaction which occurred significantly more often among patients in the treatment group vs. control (22% vs 5%, OR 5.1, 95% CI 1.5-21.7, p = .004). Two infants (3%) in the treatment group compared to none in the control group developed severe apnea within 5 minutes of treatment. No differences in decolonization were observed based on age or methicillin susceptibility. Of note, infants colonized with mupirocin-resistant S. aureus at time of admission increased throughout the study period, from 0% during study months 0-14 to 6% during the final year (p = .05). All resistant strains were observed at the center with the highest enrollment.

RELATED REPORTS

Resuscitation practices in moderate and late preterm infants are highly variable

Adjuvant erythropoietin therapy does not improve survival in newborns with hypoxic-ischemic encephalopathy

Maternal vaccination linked to lower coronavirus disease-related hospitalizations in infants

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: methicillin-resistant staph aureus (MRSA)neonatal intensive care unit (NICU)neonatologypediatric infectious diseasesstaph aureus
Previous Post

2 Minute Medicine Rewind December 24, 2018

Next Post

Quick Take: Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

RelatedReports

Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia
Pediatrics

Resuscitation practices in moderate and late preterm infants are highly variable

August 1, 2022
Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia
Emergency

Adjuvant erythropoietin therapy does not improve survival in newborns with hypoxic-ischemic encephalopathy

July 19, 2022
Large proportion of late preterm infants and older admitted to the NICU
Infectious Disease

Maternal vaccination linked to lower coronavirus disease-related hospitalizations in infants

July 19, 2022
Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia
Chronic Disease

Global mortality of neonates born preterm has decreased nearly 50 percent since 1990

June 15, 2022
Next Post
Glioblastoma phenotypes identified on MRI predict molecular behavior

Quick Take: Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Stochastic resonance stimulation may decrease apnea of prematurity

Quick Take: Small for gestational age and risk of childhood mortality: A Swedish population study

Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

New molecular probes for melanoma imaging and treatment [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Subthreshold micropulse laser is equivalent to standard laser for treating diabetic macular edema
  • Gadolinium-containing contrast associated with nephrogenic fibrosing dermopathy and systemic fibrosis [Classics Series]
  • Study supports continued use of amoxicillin as first-line therapy for pediatric ear infections
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.